Which HIV patients should be screened for osteoporosis: an international perspective

July 31, 2016 at 9:33 pm

Current Opinion In HIV and AIDS May 2016 V.11 N.3 P.268–276

Alvarez, Elena; Belloso, Waldo H.; Boyd, Mark A

aHIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland

bInfectious Diseases and Clinical Pharmacology Sections, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

cThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia

dSchool of Medicine, Hacettepe University, Ankara, Turkey

eDepartment of Infectious Diseases at Peking Union Medical College Hospital, Beijing, China

fInfectious Diseases Institute (IDI) HIV outpatient clinic at Mulago Hospital Complex, Makerere University College of Health Sciences, Kampala, Uganda

gMoscow Regional AIDS Centre, Moscow, Russia

hInfectious Diseases Unit Hospital Clinic – Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

iICH Study Center, Hamburg, Germany

jToronto General Research Institute (TGRI), University Health Network (NHN), Toronto General Hospital, Toronto, Canada

kDivision of Endocrinology, Diabetes & Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

lMater Misericordiae University Hospital, Department of Infectious Diseases, Dublin, Ireland

Purpose of review

This review provides international insights into the real-world clinical approach to screening for bone mineral density (BMD) and osteoporosis in people living with HIV (PLWH) using opinions from HIV physicians from key regions around the world.

Recent findings

Although a significant proportion of PLWH are aged over 50, the relative importance of low BMD to clinical care differs significantly between countries and regions, based on factors such as the population at risk, access to adequate screening resources, and physicians’ knowledge. Generally, management of osteoporosis in PLWH follows similar principals as for the general population, with risk factors for fracture combined with measurement of BMD by dual energy X-ray absorptiometry in algorithms such as Fracture Risk Assessment Tool, designed to provide an overall risk estimation. Although in most regions age is considered among the most important factors contributing to low BMD and fractures, considerable country and region-specific factors become apparent, such as malnutrition, inactivity and impact of comorbidities, substance abuse, and increasing use of tenofovir disoproxil fumarate.

Summary

These opinions highlight the diversity that still exists in the approach to the long-term management of PLWH and highlight challenges facing development of consensus guidelines that can be effectively implemented worldwide.

FULL TEXT

http://journals.lww.com/co-hivandaids/Fulltext/2016/05000/Which_HIV_patients_should_be_screened_for.5.aspx

PDF (CLIC in PDF)

Entry filed under: Antirretrovirales, Biología Molecular, Epidemiología, HIV/SIDA, HIV/SIDA HAART, HIV/SIDA Trastornos Oseos, Infecciones virales, Metodos diagnosticos, Update. Tags: .

How to predict the risk of fracture in HIV? Tenofovir and bone health


Calendar

July 2016
M T W T F S S
« Jun   Aug »
 123
45678910
11121314151617
18192021222324
25262728293031

Most Recent Posts


%d bloggers like this: